Pharmaceutical Stocks To Add to Your Watchlist - June 11th

Eli Lilly and Company, D-Wave Quantum, Insmed, Thermo Fisher Scientific, and Pfizer are the five Pharmaceutical stocks to watch today, according to MarketBeat's stock screener tool. Pharmaceutical stocks are shares of publicly traded companies engaged in the research, development, manufacturing and marketing of medications and medical therapies. Their performance is driven by factors such as clinical trial outcomes, regulatory approvals, patent protections and broader healthcare demand, making them potentially lucrative but sometimes volatile investments. These companies had the highest dollar trading volume of any Pharmaceutical stocks within the last several days.

Eli Lilly and Company (LLY)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

Shares of NYSE LLY traded up $5.07 during mid-day trading on Wednesday, hitting $812.26. The company had a trading volume of 1,623,239 shares, compared to its average volume of 3,647,178. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a market capitalization of $769.81 billion, a price-to-earnings ratio of 69.42, a P/E/G ratio of 1.40 and a beta of 0.41. The stock's 50-day moving average price is $770.33 and its 200-day moving average price is $800.86.

Read Our Latest Research Report on LLY

D-Wave Quantum (QBTS)

D-Wave Quantum Inc. develops and delivers quantum computing systems, software, and services worldwide. The company offers Advantage, a fifth-generation quantum computer; Ocean, a suite of open-source python tools; and Leap, a cloud-based service that provides real-time access to a live quantum computer, as well as access to Advantage, hybrid solvers, the Ocean software development kit, live code, demos, learning resources, and a vibrant developer community.

QBTS stock traded down $0.47 during mid-day trading on Wednesday, reaching $16.46. 67,568,861 shares of the company traded hands, compared to its average volume of 45,273,006. The company has a market capitalization of $4.81 billion, a P/E ratio of -39.12 and a beta of 1.49. D-Wave Quantum has a 52-week low of $0.75 and a 52-week high of $19.77. The company has a fifty day moving average price of $10.97 and a 200-day moving average price of $8.00.

Read Our Latest Research Report on QBTS

Insmed (INSM)

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.

Shares of Insmed stock traded up $6.53 on Wednesday, reaching $97.46. The stock had a trading volume of 8,616,358 shares, compared to its average volume of 2,142,992. The business's 50 day moving average is $69.58 and its two-hundred day moving average is $73.14. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03. Insmed has a 1 year low of $57.92 and a 1 year high of $98.88. The company has a market cap of $17.75 billion, a P/E ratio of -17.47 and a beta of 0.80.

Read Our Latest Research Report on INSM

Thermo Fisher Scientific (TMO)

Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

NYSE TMO traded down $0.04 on Wednesday, hitting $414.51. The stock had a trading volume of 1,610,042 shares, compared to its average volume of 1,915,248. The firm has a 50-day moving average of $418.02 and a 200-day moving average of $494.38. The company has a market capitalization of $156.47 billion, a price-to-earnings ratio of 25.12, a price-to-earnings-growth ratio of 2.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. Thermo Fisher Scientific has a 52-week low of $390.50 and a 52-week high of $627.88.

Read Our Latest Research Report on TMO

Pfizer (PFE)

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

Shares of PFE stock traded up $0.13 on Wednesday, reaching $24.43. The company's stock had a trading volume of 21,587,261 shares, compared to its average volume of 40,963,888. The company has a market capitalization of $138.87 billion, a P/E ratio of 17.32, a PEG ratio of 0.64 and a beta of 0.57. Pfizer has a 12-month low of $20.92 and a 12-month high of $31.54. The stock's 50 day simple moving average is $22.93 and its 200-day simple moving average is $24.98. The company has a quick ratio of 0.73, a current ratio of 1.00 and a debt-to-equity ratio of 0.63.

Read Our Latest Research Report on PFE